Globus Medical, Inc. (GMED) News
Filter GMED News Items
GMED News Results
|Loading, please wait...|
GMED News Highlights
- GMED's 30 day story count now stands at 10.
- Over the past 15 days, the trend for GMED's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about GMED are NOV, AKAM and AXON.
Latest GMED News From Around the Web
Below are the latest news stories about GLOBUS MEDICAL INC that investors may wish to consider to help them evaluate GMED as an investment opportunity.
In this article, we discuss 13 best robotics stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Robotics Stocks To Buy Now. The global robotics market was worth $27.73 billion in 2020 and is forecasted to reach $74.1 billion by 2026, indicating a CAGR of 17.45% […]
In this article, we will take a look at the 15 biggest medical device companies in the world. If you want to skip our introduction to the industry, then take a look at 5 Biggest Medical Device Companies in the World. The medical device market comprises companies that manufacture equipment used in diagnosing, treating and surveillance […]
Globus Medical Partners with the UK’s NHS to Provide Hospitals with Surgical Robotic Navigation Technology
First Robotic Assisted Spine Surgeries Performed at Two NHS Trust Hospitals with Globus Medical’s ExcelsiusGPS®AUDUBON, Pa., Nov. 17, 2022 (GLOBE NEWSWIRE) -- The NHS and Globus Medical have partnered to provide state-of-the-art robotic navigation technology for spinal surgery to NHS hospitals across the United Kingdom. This partnership will allow NHS Trust hospitals to seamlessly implement the ExcelsiusGPS® robotic assisted spine system into operating theatres, providing patients and surgeons w
Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...
Companies In The News Are: AKAM, AXON, GMED, SRC.
Needham analyst David Saxon reiterated a Buy rating on Globus Medical (GMED - Research Report) today and set a price target of $71.00. The company's shares closed yesterday at $64.29.According to TipRanks, Saxon is an analyst with an average return of -18.3% and a 17.02% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Glaukos, Alphatec Holdings, and Cooper Co.Currently, the analyst consensus on Globus Medical is a Strong Buy with an average price target of $70.40, representing a 9.50% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $71.00 price target.
Joining today's call from Globus Medical will be Dan Scavilla, president and CEO; and Keith Pfeil, senior vice president and chief financial officer. This review is being made available via webcast accessible through the investor relations section of the Globus Medical website at www.globusmedical.com.
Globus Medical (GMED) delivered earnings and revenue surprises of -3.85% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AUDUBON, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022. Worldwide net sales were $254.1 million, an increase of 10.6%, or 12.6% on a constant currency basisGAAP net income for the quarter was $47.4 millionGAAP diluted earnings per share (“EPS”) was $0.47 and non-GAAP diluted EPS was $0.50Non-GAAP adjusted EBITDA was $82.8 million, or 32.6% of net